Table 3

 Patients with treatment-emergent adverse events (⩾3%)

Etanercept 50 mg once weekly (n = 155)Etanercept 25 mg twice weekly (n = 150)Placebo (n = 51)
Values are n (%).
*Excluding injection site reactions and infections.
†Serious infections, erysipelas, was reported in the right ankle of one patient receiving etanercept 50 mg QW, and Streptococcus pyogenes at the insulin catheter site in one patient with diabetes receiving etanercept 25 mg BIW.
Non-infectious adverse events
    Any adverse event*55 (35.5)66 (44.0)18 (35.3)
    Injection site reactions32 (20.7)34 (22.7)6 (11.8)
    Back pain1 (0.6)1 (0.7)3 (5.9)
    Abdominal pain5 (3.2)6 (4.0)1 (2.0)
    Nausea3 (1.9)5 (3.3)2 (3.9)
    Overdose6 (3.9)4 (2.7)1 (2.0)
    Headache6 (3.9)4 (2.7)0 (0.0)
    Diarrhoea6 (3.9)4 (2.7)0 (0.0)
Infectious adverse events
    Any infection†35 (22.6)33 (22.0)12 (23.5)
    Upper respiratory infection12 (7.7)12 (8.0)7 (13.7)
    Pharyngitis or laryngitis6 (3.9)3 (2.0)0 (0)